Nuvectis Pharma, Inc.
$8.33
▼
-0.53%
2026-04-21 08:31:00
www.nuvectis.com
NCM: NVCT
Explore Nuvectis Pharma, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$235.78 M
Current Price
$8.33
52W High / Low
$11.52 / $5.55
Stock P/E
—
Book Value
$0.72
Dividend Yield
—
ROCE
-149.75%
ROE
-1.88%
Face Value
—
EPS
$-1.32
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
13
Beta
-0.21
Debt / Equity
—
Current Ratio
2.38
Quick Ratio
2.38
Forward P/E
-8.56
Price / Sales
—
Enterprise Value
$186.13 M
EV / EBITDA
—
EV / Revenue
—
Rating
None
Target Price
$16.8
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | MiMedx Group, Inc. | $3.25 | 10.44 | $507.35 M | — | 22.95% | 21.61% | $7.99 / $3.31 | $1.73 |
| 2. | Cibus, Inc. | $1.56 | — | $118.83 M | — | -23.41% | -2.21% | $4.19 / $1.09 | $0.4 |
| 3. | aTyr Pharma, Inc. | $0.85 | — | $83.68 M | — | -99.71% | -1.08% | $7.29 / $0.64 | $0.69 |
| 4. | Kiora Pharmaceuticals, Inc. | $2.52 | — | $9.96 M | — | -45.87% | -51.74% | $4.18 / $1.76 | $4.29 |
| 5. | Soligenix, Inc. | $1.38 | — | $14.22 M | — | -213.96% | -2.35% | $6.23 / $1 | $0.77 |
| 6. | Vyome Holdings, Inc. | $2.35 | — | $16.49 M | — | -73.02% | 1053.07% | $56.36 / $1.75 | $0.41 |
| 7. | Aktis Oncology, Inc. | $20.83 | — | $1.08 B | — | -31.96% | -29.45% | $29.16 / $14.72 | $-159.68 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -7.62 M | -7.79 M | -6.59 M | -5.57 M | -6.45 M | — |
| Net Profit | -7.31 M | -7.46 M | -6.33 M | -5.33 M | -6.25 M | — |
| EPS in Rs | -0.28 | -0.28 | -0.24 | -0.2 | -0.24 | -0.24 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -27.57 M | -19.85 M | -22.9 M | -19.23 M |
| Net Profit | -26.44 M | -19 M | -22.26 M | -19.09 M |
| EPS in Rs | -1 | -0.72 | -0.84 | -0.72 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 31.71 M | 18.61 M | 19.18 M | 20.41 M |
| Total Liabilities | 13.3 M | 8.89 M | 6.98 M | 6.19 M |
| Equity | 18.41 M | 9.71 M | 12.2 M | 14.22 M |
| Current Assets | 31.71 M | 18.61 M | 19.18 M | 20.41 M |
| Current Liabilities | 13.3 M | 8.89 M | 6.98 M | 6.19 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -16.01 M | -12.25 M | -15.95 M | -13.56 M |
| Investing CF | 0 M | 0 M | 0 M | 0 M |
| Financing CF | 29.11 M | 11.65 M | 15.09 M | 27.81 M |
| Free CF | -16.01 M | -12.25 M | -15.95 M | -13.56 M |
| Capex | — | — | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 14.65% | -16.64% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.